Molina-Collada, J, Alonso, F, Otero, L, Bohórquez, C, Torné, CD, García, CP, Madrigal, JMB, Vela, P, Alvaro-Gracia, JM, Castrejón, I. Cancer risk with biologic and targeted synthetic DMARDs in patients with rheumatic diseases and previous malignancies: Results from the BIOBADASER register. SEMINARS IN ARTHRITIS AND RHEUMATISM. 2024; 64DOI:10.1016/j.semarthrit.2023.152341. PMID:38128174. IF:4.400(Q1/1D).

López-Medina, C, Calvo-Gutiérrez, J, Abalos-Aguilera, MC, Cepas, F, Plasencia-Rodríguez, C, Martínez-Feito, A, Balsa, A, Faré-García, R, Juan-Mas, A, Ruiz-Esquide, V, Sainz, L, Díaz-Torné, C, Godoy-Navarrete, FJ, Añón-Oñate, I, Mena-Vázquez, N, Manrique-Arija, S, Moreno-García, MS, Ortega-Castro, R, Escudero-Contreras, A. Exploring the influence of baseline rheumatoid factor levels on TNF inhibitor retention rate in patients with rheumatoid arthritis: a multicentre and retrospective study. RMD Open. 2024; 10(1)DOI:10.1136/rmdopen-2023-003975. PMID:38395455. IF:4.700(Q1/1D).

Castellá, M, Mestres-Arenas, A, Gavaldà-Navarro, A, Blasco-Roset, A, Quesada-López, T, Romero-Carramiñana, I, Giralt, M, Villarroya, F, Cereijo, R. The splicing factor SF3B1 is involved in brown adipocyte thermogenic activation. BIOCHEMICAL PHARMACOLOGY. 2024; 220DOI:10.1016/j.bcp.2023.116014. PMID:38158020. IF:5.600(Q1/1D).

Schreurs, MAC, Cajal, TRY, Adank, MA, Collee, JM, Hollestelle, A, van Rooij, J, Schmidt, MK, Hooning, MJ. The benefit of adding polygenic risk scores, lifestyle factors, and breast density to family history and genetic status for breast cancer risk and surveillance classification of unaffected women from germline CHEK2 c.1100delC families. BREAST. 2024; 73DOI:10.1016/j.breast.2023.103611. PMID:38039887. IF:7.900(Q1/1D).

Villarrubia, JE, Gordoa, TA, Mellado-González, B, Duran, I, Pinto, A, Sanchez, A, Pous, AF, Vazquez-Estevez, S, Puente, J, Grande, E, Climent, MA, Maroto-Rey, P, Perez-Gracia, JL, Aix, SP, Castellano, D, Gonzalez-Billalabeitia, E. Peapod FOS trial: A phase 2 clinical trial of pembrolizumab in combination with carboplatin and cabazitaxel in aggressive variant metastatic castration-resistant prostate cancer.. JOURNAL OF CLINICAL ONCOLOGY. 2024; 42(4_SUPPL)DOI:10.1200/JCO.2024.42.4_suppl.TPS238. PMID:. IF:41.900(Q1/1D).

Pujol, A, León, X, Holgado, A, Valero, C, Kolanczak, K, Quer, M, Virós, D. External validation of the GETTEC algorithm for elective neck dissection in patients candidates for salvage total laryngectomy. ORAL ONCOLOGY. 2024; 149DOI:10.1016/j.oraloncology.2024.106686. PMID:38218021. IF:3.900(Q1/2D).